華北製藥(600812.SH):注射用頭孢他啶阿維巴坦鈉獲得《藥品註冊證書》
格隆匯6月10日丨華北製藥(600812.SH)公佈,全資子公司華北製藥河北華民藥業有限責任公司(簡稱“華民公司”)收到國家藥品監督管理局核准簽發的注射用頭孢他啶阿維巴坦鈉(2.5g)的《藥品註冊證書》,本品國內批准的適應症為用於治療革蘭陰性菌(包括頭孢他啶耐藥菌)感染的患者,包括複雜性腹腔內感染(cIAI);醫院獲得性肺炎(HAP),包括呼吸機相關性肺炎(VAP);在治療方案選擇有限的成人患者中治療由下列對本品敏感的革蘭陰性菌引起的感染:肺炎克雷伯菌、陰溝腸桿菌、大腸埃希菌、奇異變形桿菌和銅綠假單胞菌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.